menu search

RLFTY / Relief Therapeutics to Present Pre-Clinical Evidence for Improved Amino Acid Utilization with PKU GOLIKE at the Society for Inherited Metabolic Disorders 44th Annual Meeting

Relief Therapeutics to Present Pre-Clinical Evidence for Improved Amino Acid Utilization with PKU GOLIKE at the Society for Inherited Metabolic Disorders 44th Annual Meeting
The results of the preclinical study demonstrate improved muscle anabolism and function with a prolonged-release amino acid supplement using Physiomimic Technology™ GENEVA, SWITZERLAND / ACCESSWIRE / March 17, 2023 / RELIEF THERAPEUTICS Holding SA (SIX:RLF) (OTCQB:RLFTF) (OTCQB:RLFTY) ("Relief Therapeutics"), a biopharmaceutical company committed to advancing treatment paradigms and delivering improvements in efficacy, safety and convenience to benefit the lives of patients living with rare diseases, today announced the Company will present the results of pre-clinical research evaluating the metabolic impact of PKU GOLIKE® on nitrogen balance, muscle strength and glucose. The data will be presented in a poster session at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting in Salt Lake City, March 18-21, 2023. Read More
Posted: Mar 17 2023, 18:25
Author Name: Accesswire
Views: 122472

RLFTY News  

Relief Therapeutics to Present Pre-Clinical Evidence for Improved Amino Acid Utilization with PKU GOLIKE at the Society for Inherited Metabolic Disorders 44th Annual Meeting

By Accesswire
March 17, 2023

Relief Therapeutics to Present Pre-Clinical Evidence for Improved Amino Acid Utilization with PKU GOLIKE at the Society for Inherited Metabolic Disorders 44th Annual Meeting

The results of the preclinical study demonstrate improved muscle anabolism and function with a prolonged-release amino acid supplement using Physiomim more_horizontal


Search within

Pages Search Results: